Nov 16, 2022 / 08:10AM GMT
Peter James Welford - Jefferies LLC, Research Division - Senior Equity Analyst & European Pharmaceuticals Analyst
My name is Peter Welford. I'm the European pharma biotech and life sciences analyst at Jefferies in London. My pleasure to be hosting the next company in this track, which is QIAGEN. Here from QIAGEN, we have the CFO, standing up there, Roland Sackers; and we also have Phoebe Loh from IR as well with me on the table. It's a fireside chat. Roland is going to make a few introductory remarks, and then we'll open for Q&A. (Operator Instructions)
We'd love to get questions if you do have them. But with that, over to you, Roland. Thank you.
Roland Sackers - Qiagen N.V. - CFO, MD & Member of Management Board
Yes. And thanks, Peter. Thanks for having us. It's always good to see you again and have physical meetings. It clearly makes a difference even if sometimes carry too many people in small hotel rooms, but it's a different story.
Nevertheless, you might have seen that we just last week released results, and we had a very
Qiagen NV at Jefferies London Healthcare Conference Transcript
Feb 11, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers